Paracrine effects of bone marrow mononuclear cells in survival and cytokine expression after 90% partial hepatectomy by Kieling, Carlos Oscar et al.
Research Article
Paracrine Effects of Bone Marrow Mononuclear Cells in Survival
and Cytokine Expression after 90% Partial Hepatectomy
Carlos Oscar Kieling,1,2 Carolina Uribe-Cruz,1,2,3 Mónica Luján López,3,4
Alessandro Bersch Osvaldt,5 Themis Reverbel da Silveira,1,2 and Ursula Matte3,4,6
1Experimental Laboratory of Gastroenterology and Hepatology, HCPA, Ramiro Barcelos 2350, 90035-903 Porto Alegre, RS, Brazil
2Post-Graduation Program on Medicine: Sciences in Gastroenterology, UFRGS, Ramiro Barcelos 2350,
90035-903 Porto Alegre, RS, Brazil
3Gene Therapy Center, HCPA, Ramiro Barcelos 2350, 90035-903 Porto Alegre, RS, Brazil
4Post-Graduation Program on Genetics andMolecular Biology, UFRGS, Av. Bento Gonçalves 9500, 91501-970 Porto Alegre, RS, Brazil
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Acute liver failure is a complex and fatal disease. Cell-based therapies are a promising alternative therapeutic approach for liver
failure due to relatively simple technique and lower cost. The use of semipermeable microcapsules has become an interesting tool
for evaluating paracrine effects in vivo. In this study, we aimed to assess the paracrine effects of bone marrow mononuclear cells
(BMMC) encapsulated in sodium alginate to treat acute liver failure in an animal model of 90% partial hepatectomy (90% PH).
Encapsulated BMMC were able to increase 10-day survival without enhancing liver regeneration markers. Gene expression of Il-6
and Il-10 in the remnant liver was markedly reduced at 6 h after 90% PH in animals receiving encapsulated BMMC compared to
controls. This difference, however, was neither reflected by changes in the number of CD68+ cells nor by serum levels of IL6. On
the other hand, treated animals presented increased caspase activity and gene expression in the liver. Taken together, these results
suggest that BMMC regulate immune response and promote apoptosis in the liver after 90% PH by paracrine factors.These changes
ultimately may be related to the higher survival observed in treated animals, suggesting that BMMCmay be a promising alternative
to treat acute liver failure.
1. Introduction
Acute liver failure is a complex and fatal disease, character-
ized by jaundice, coagulopathy, and hepatic encephalopathy
[1]. The etiology varies from viral hepatitis, drug-induced
hepatotoxicity, and metabolic liver disease to uncertain
causes [1, 2]. Liver transplantation remains the only proven
treatment for end-stage liver failure but is limited by the
availability of donor organs [1, 3].
Cell-based therapies are a promising alternative ther-
apeutic approach for liver failure due to relatively simple
technique and lower cost [3, 4]. Several preclinical and
clinical experiments have been reported on the safety and
efficacy of bone-marrow-derived mononuclear cells to treat
liver disorders [5–8].
Recently, one of the best studied mechanisms of action
for these cells is the release of paracrine factors cells [9].
However, the pathway in which they act has still not been
fully clarified mainly by the difficulty of in vivo studies.
The use of semipermeable microcapsules has become an
interesting tool for evaluating paracrine effects in vivo.These
microcapsules can immune-isolate xenogeneic cells allowing
the exchange of low-molecular-weight nutrients and oxygen
across the membranes [10]. In this study, we aimed to
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assess the paracrine effect of bone marrowmononuclear cells
(BMMC) encapsulated in sodium alginate to treat acute liver
failure in an animal model of 90% partial hepatectomy.
2. Materials and Methods
2.1. Animals. Two-month-old male Wistar rats (298 ± 60 g)
were kept under controlled temperature (between 18 and
22∘C) in 12 h light-dark cycles with free access to water and
standard chow at Experimental Animal Unit at Hospital de
Cĺınicas de Porto Alegre (HCPA). Handling, care, and pro-
cessing of animals were carried out according to regulations
approved by our local Ethics Committee and complied with
the National Guidelines on Animal Care.
2.2. Experimental Design. Rats were randomly divided into
two groups. Treated group received encapsulated bone mar-
row mononuclear cells (BMMC, 𝑛 = 39) and control group
(𝑛 = 41) received empty capsules (EC). Survival was observed
for up to 10 days after 90% PH.
To evaluate the early effects of treatments an additional set
of animals were randomly divided into two groups (BMMC
and EC) and euthanized at 6, 12, 24, 48, and 72 hours after
90% PH (𝑛 = 6–8/group/time point). For mononuclear bone
marrow cells 5 animals were used as donors and another 5
animals without liver injury were used as normal controls.
2.3. Isolation of BMMC. Five näıve male Wistar rats were
used as BMMC donors as described by Matte et al. [11].
Briefly, in a sterile environment, the femurs and tibias were
isolated and whole bone marrow was flushed with complete
medium: DMEM (Dulbecco’s Modified Eagle Medium, LGC,
Brazil) supplemented with 10% fetal bovine serum (Gibco,
USA), 1% penicillin/streptomycin (Gibco, USA) and cen-
trifuged at 800 g for 5 minutes. The pellet was diluted in
complete medium and then placed onto a Ficoll Histopaque
(GE-Healthcare, USA) layer and centrifuged at 800 g for
30min. The interface was separated using a pipette, and cells
were rinsed with PBS three times. Cells were counted using
the Neubauer chamber and Trypan Blue exclusion test to
verify cell viability.
2.4. Cell Encapsulation. Cell encapsulation was performed
according to our laboratory protocol, previously described
[12]. Briefly, BMMC were mixed with 1.5% sodium alginate
(Sigma-Aldrich, USA) in complete medium and extruded
through a Encapsulation Unit, type J1 (Nisco, Switzerland),
attached to JMS Syringe Pump. Droplets were sheared off
with an air flow of 5 L/min delivered to the tip of a 27G
needle and the rate of infusion was 40mL/h. The droplets





+ to form solid spherical hydrogel beads containing
embedded BMMC. In eachwell capsules were produced from
a volume of 2mL of alginate suspension, containing 1 × 106
BMMC/animal. BMMC encapsulation was carried out under
sterile conditions. For control group, 2mL of empty capsules
was produced using the same approach, although without
cells. The resulting capsules were maintained under normal
cell culture conditions with completemedium at 37∘C and 5%
CO
2
for 24 h prior to administration.
2.5. Animal Model of 90% Partial Hepatectomy and Cap-
sules Transplantation. Hepatectomy was carried out under
isoflurane (Forane, Abbott SA, Argentina) anesthesia [13].
An abdominal midline incision was made to expose the
liver. Ninety percent hepatectomy was performed by a single
operator as described by Gaub and Iversen (1984) [14]. In
brief, the left lateral (30%), left median (40%), and right
superior lobes (20%) were removed, leaving only the caudate
lobes. Immediately after 90% PH, as well as before complete
suture, microcapsules (either empty or containing BMMC)
were placed into the peritoneal cavity and glucose was
supplemented i.p. (5% of body weight).The incision was then
closed. After the rats recovered from anesthesia, animals were
given i.p. glucose (5% of body weight) until day seven and
received 20% glucose in their drinking water and standard
chow ad libitum until euthanasia.
2.6. Euthanasia. Euthanasia was performed in CO
2
cham-
bers at the 6, 12, 24, 48, and 72 h or at 10 days after 90%
PH. Immediately after euthanasia bloodwas collected and the
serumwas kept at −80∘C until analysis; the liver was removed
and weighed and part was flash-frozen in liquid nitrogen and
the rest was placed in 10% buffered formalin. At each time
point and every day until day 10 animals were weighed.
2.7. Liver Regeneration Rate. The liver regeneration rate [15]
was calculated as follows: liver regeneration rate (%) = 100 ×
[𝐶 − (𝐴 −𝐵)]/𝐴, where 𝐴 is the estimated liver weight before
PH, 𝐵 is the excised liver weight at the time of PH, and 𝐶 is
the weight of the regenerated liver at the time of euthanasia.
2.8. Histology and Immunohistochemistry. Paraffin-embed-
ded liver specimens were cut in 4𝜇m sections and stained
with hematoxylin and eosin (H-E). Mitotic index was per-
formed by counting the number of hepatocytes undergoing
mitosis in 10 high power fields (HPF) at each time point until
72 h after 90% PH [6].
To assess the rate of hepatocyte proliferation, the number
of hepatocytes undergoing mitosis was counted in 10 HPF. In
addition, 5-bromo-2󸀠-deoxyuridine (BrdU) immunostaining
was done using BrdU staining kit (Invitrogen, USA). Two
hours before sacrifice, rats (𝑛 = 3/group) were injected with
BrdU (1mL/g).Thereafter, liver sections were incubated with
BrdU antibody and the number of positive hepatocytes was
counted in 5 HPF.
2.9. Serum Cytokine Levels. Serum level of IL-6 was quanti-
fied by enzyme-linked immunosorbent assay (ELISA) using
commercial kits (R&D Systems, Minneapolis, Minnesota,
EUA) in accordance with the manufacturer’s instructions.
2.10. Quantitative Real-Time PCR. Total RNA was extracted
from liver tissue (∼50mg) using TRIzol reagent (Invitrogen,
USA) according to the manufacturer’s instructions and 2 𝜇g
was reverse-transcribed using High Capacity cDNA Reverse
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TranscriptionKit (Life Technologies, USA).The expression of
genes involved in inflammation pathway (Interleukins 6 and
10) and apoptosis (Caspase 3) were measured using TaqMan
assays (Life Technologies, USA).Thepercentage of a test RNA
to that of 𝛽-actin was calculated by subtracting the cycle to
reach the threshold (CT) for that gene from theCT for𝛽-actin
to determine the ΔCT, and the formula is percent 𝛽-actin =
(100) × 2ΔCT [12]. The percent 𝛽-actin for hepatectomized
animals was divided by the percent𝛽-actin in normal animals
to determine the ratio of gene expression in both treatments
after 90% PH to normal rats. Livers of animals without injury
were used as calibrator group (normal values = 1).
2.11. Immunohistochemistry Analysis. Paraffin-embedded liv-
er specimens were cut in 4𝜇m sections and Kupffer cells
were quantified by immunostaining for CD68. For that, liver
sections were incubated overnight at 4∘C with the primary
antibody rabbit IgG-CD68 (1 : 800, Abcam,USA) andwashed
with phosphate buffer Tween 20; then universal biotinylated
link and streptavidin-HRP were added (Dako, USA) and
revealed with DAB kit (Dako, USA). The slides were coun-
terstained with hematoxylin.The number of CD68+ cells was
counted in 5 randomly selected HPF (×400) per slide.
2.12. Caspase 3 Activity. Fluorometric Caspase 3 activity
(Sigma-Aldrich, USA) assays were performed according
to the manufacturer’s instructions. Briefly, 15 𝜇L of liver
homogenate in PBS was placed in an opaque 96-well plate
and 200𝜇L of mixture reaction solution (containing Acetyl-
Asp-Glu-Val-Asp-7-amido-4-methylcoumarin) was added to
eachwell.Theplatewas incubated in dark at 25∘Cand every 10
minutes the fluorescencewas read at 360 nmof excitation and
460 of emission. Caspase activity was normalized by protein
measured by Lowry method [16].
2.13. Statistical Analysis. Results were expressed as means ±
standard deviation (SD) ormedianswhen required. Statistical
differences were assessed by Student’s 𝑡-test and for nonpara-
metric variables Mann–Whitney test was used. The survival
rate was analyzed by Kaplan-Meier curve. The comparison
of survival rates in different groups was tested by the log
rank test. 𝑃 values less than 0.05 were considered statistically
significant.
3. Results
3.1. BMMC Increase Survival Rate in Rats with 90% Partial
Hepatectomy. Survival rate was accompanied during 10 days
after 90% PH. The survival rate in BMMC group was
higher (54.5%) than EC group (5%; 𝑃 = 0.003; Figure 1).
Interestingly, the peak of death in BMMC group occurred
within the first three days after PH. In contrast, animals in EC
group died over time.Thus, the next analyses were performed
until 72 hours after 90% PH to address the beneficial effect of
encapsulated BMMC.
3.2. BMMCDoNot Enhance Liver Regeneration. To address if
the increase of survival rate in BMMC was a consequence of
a higher liver regeneration, we calculated liver regeneration
EC (n = 15)
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Figure 1: Survival rate for 10 days after 90% partial hepatectomy
(PH). BMMC increase survival rate in rats submitted to PH (∗𝑃 =
0.003, log rank test). EC: empty capsules, BMMC: encapsulated bone
marrow mononuclear cells.
rate until 72 hours after PH. Liver size increased over time
in both groups and at 72 h the BMMC group reached 39%
of the original liver weight, whereas EC group reached 46%
(Figure 2(a)). In addition, the number ofmitosis (Figure 2(b))
and positive hepatocytes for BrdU (Figures 2(c) and 2(d)) was
also similar between groups. Therefore, BMMC do not seem
to enhance liver regeneration after 90% PH.
3.3. BMMC Modulate Cytokines. It is well known that BMM
have immunomodulatory properties [17]. Thus, in order to
investigate the impact of immunomodulation on survival,
we studied serum level of Interleukin-6 (IL-6) and its gene
expression in the remnant livers. Serum IL-6 levels were
increased in both groups at 6 h after 90% PH (268 pg/mL for
EC group and 298 pg/mL for BMMC group, 𝑃 = 0.9), but it
decreased to normal range from 12 h in both groups equally
(see Supplementary Figure 1 of the Supplementary Mate-
rial available online at https://doi.org/10.1155/2017/5270527).
However, in the remnant livers, we observed an increase in
Il-6 expression in both groups until 24 hours after 90% PH
compared to normal values. However, in BMMC group, this
increase is lower (5-fold increase) at 6 hours when compared
to EC group (25-fold increase, 𝑃 = 0.03). From 12 h after PH,
the expression in EC group decreased to about 2-fold normal
values, whereas in BMMC it remained around 3–6 times
higher than normal, albeit this difference is not statistically
significant (Figure 3(a)).
On the other hand, for IL-10 liver gene expression a
diverse outcome was observed. At 6 h after 90% PH BMMC
group showed near to normal expression values, whereas
EC group showed a 12-fold increase compared to normal
animals (Figure 3(b), 𝑃 < 0.001 comparing BMMC versus
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Figure 2: (a) Liver regeneration rate at 6, 12, 24, 48, and 72 hours after 90% partial hepatectomy (PH). (b) Mitotic index at 6, 12, 24, 48, and
72 hours after 90% PH. (c) BrdU immunohistochemistry, BMMC 48 hours after 90% partial hepatectomy (20x). (d) Positive hepatocytes for
BrdU, EC, and BMMC 24: 12.72 ± 12.38 and 5.9 ± 5.3, respectively; EC and BMMC 48: 10.34 ± 5.03 and 9.46 ± 3.49, respectively. Values are
expressed as means ± SD. Student’s 𝑡-test. EC: empty capsules, BMMC: encapsulated bone marrow mononuclear cells.
EC groups). In the following hours (12 and 24 h after 90%
PH) BMMC group remains close to normal values, whereas
in EC group a sharp reduction in IL-10 expression is observed
(𝑃 < 0.001 and 𝑃 = 0.02, resp.). At 48 and 72 h, though,
BMMC show a reduction in expression.
3.4. Cytokine Modulation Is Not Related to the Number
of Kupffer Cells. Kupffer cells (KC) are the macrophages
resident in the liver and have an essential role in liver injuries
by secreting cytokines and priming hepatocytes for division.
To address if the expression of cytokines in the liver were
was related to the number of KC, we assessed the number of
CD68+ cells in liver sections. We note that in general there is
no difference in the amount of KC cells between the groups
except at 12 hours, when BMMC group showed an increase
when compared to EC group (𝑃 = 0.003; Figure 4).
3.5. BMMC Benefits Apoptosis. In a previous study [12], we
showed that encapsulated whole bone marrow cells increase
apoptosis after 90% PH. Therefore, we analyzed Caspase
3 activity and its expression in the remnant liver. It was
observed that BMMC group showed more Caspase 3 activity
mainly at 24, 48, and 72 h after 90% PH (𝑃 < 0.05;
Figure 5(a)).This result is consistent with the gene expression
data, which also was high in BMMC group compared to EC
group (𝑃 < 0.05; Figure 5(b)).
4. Discussion
The use of BMMC in cell therapy is a suitable approach
due to its easy standardized protocol for cell collection and
promising benefits in the treatment of liver disease [5, 18].
However, before this therapy can be widely accepted in the
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Figure 3: BMMCmodulate liver cytokines. Liver gene expression of Il-6 (a) and Il-10 (b) at 6, 12, and 24 hours after 90% partial hepatectomy
(PH). Values are expressed as means ± SD in log scale. Student’s 𝑡-test, ∗𝑃 < 0.05. EC: empty capsules, BMMC: encapsulated bone marrow
mononuclear cells.
(a) (b)
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Figure 4: CD68+ cells in liver sections, EC, and BMMC 72 hours after 90% partial hepatectomy ((a) and (b), resp.). (c) CD68 + cell
quantification at 6, 12, 24, 48, and 72 hours after 90% partial hepatectomy (PH). Values are expressed as means ± SD. Student’s 𝑡-test,
∗
𝑃 = 0.003. EC: empty capsules, BMMC: encapsulated bone marrow mononuclear cells. Horizontal bar indicates normal values.
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Figure 5: BMMC enhance apoptosis. (a) Caspase 3 activity and (b) liver gene expression of Caspase 3 after 90% partial hepatectomy. Values
are expressed as means ± SD. Student’s 𝑡-test, ∗𝑃 < 0.05. EC: empty capsules, BMMC: encapsulated bone marrow mononuclear cells.
clinic, its mechanisms of action must be better elucidated.
Several studies have shown that BMMC have immunomodu-
latory properties [17, 19], focusing the attention of researchers
on their paracrine effect [9]. In this sense, the use of
microcapsules allows the communication between the cell
entrapped within the capsule and the environment where
they are implanted without cell-to-cell interaction [20]. In
this study we evaluate the paracrine effect of BMMC using
semipermeablemicrocapsules in rats with 90% PH, a suitable
model for analyzing induced acute liver damage [21, 22].
The first result of our study showed a marked increase
in survival rate in BMMC group which is consistent with
other studies of cell therapy for acute liver disease using toxic
models [6, 7, 23]. Other studies, using surgical models of
90% PH, such as Liu and Chang (2006) [24] and Uribe-Cruz
et al. (2016) [12], also observed an increase in survival in
animals treated with encapsulated cells, but both groups used
encapsulated whole bone marrow cells, without separation of
mononuclear cells.
In order to study the reasons for increased survival
in BMMC group, we analyzed liver regeneration, which
is a widely used method to assess recovery after partial
hepatectomy [25, 26]. Liver regeneration rate, assessed either
by liver weight, mitotic index, or BrdU, was similar in both
groups suggesting that the increase in survival is not related
to tissue regeneration. One must note that this is a 90%
partial hepatectomy and not a classical liver regeneration
model, such as 70% PH. So, although liver regeneration is
essential for survival, different works point to other factors
that influence recovery, including the pace of regeneration
[27]. In addition, other studies from our group also point
to a positive impact in survival that is not directly linked to
hepatocyte regeneration [12, 28]. Thus, it is suggested that
BMMC improve survival through mechanisms other than
enhancing hepatocyte proliferation.
Acute liver failure promotes a shock septic response by
the immune system [27, 28], leading to a disequilibrium in
the levels of pro- and anti-inflammatory cytokines [29]. It is
well recognized that IL-6 and IL-10 have an important role
in improving recovery after acute liver failure [29, 30]. Thus,
we analyzed the paracrine effect of BMMC on hepatic gene
expression of Il-6 and Il-10 after liver injury. We observed
that both experimental groups showed an increase in Il-6
expression at 6 h after 90% PH; however in BMMC group
this increase was much lower than in EC group. On the other
hand, in BMMC-treated animals Il-6 expression remains
slightly elevated until 24 h after 90% PH.The expression of Il-
10 in BMMC group was also closer to normal levels, whereas
in EC group it was increased at 6 h and greatly reduced at 12
hours after 90% PH. It is important to notice that Il-6 is a
major inducer of hepatic acute phase response and its expres-
sion plays a central role in restoring normal hepatic function
following liver injury [31]. On the other hand, Il-10 is a potent
anti-inflammatory cytokine and selectively blocks proinflam-
matory genes in the liver after PH and reduces the number of
macrophages and monocytes in the liver [32]. Moreover, the
prevalence of an anti- or proinflammatory response results in
the loss of immunohomeostasis and death [33]. So it can be
suggested that the effect of BMMC ismaintaining the balance
between pro- and anti-inflammatory cytokines.
To address if the expression of cytokines in the liver
was related to the number of KC, we assessed the number
of CD68+ cells in liver sections. Normal Wistar rats have
between 50 and 70 CD68+ cells, and this number does not
increase significantly after 90% PH, except at 12 h, when
BMMC show an average of 110 CD68+ cells. This lack
of statistical difference may be due to the high variability
observed among animals in both groups at any time point.
There are some works showing that these cytokines
stimulate apoptosis in liver cells [34]. Our results show
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an increase in Caspase 3 activity and gene expression in
BMMC group when compared to EC group at 24 and 48
hours. These results are in agreement with the suggestion
that apoptosis eliminates unwanted or harmful cells to
maintain homeostasis and normal tissue functioning [35].
It is a pathophysiological beneficial process that regulates
growth and proliferation, thus ensuring proper organ size and
function [36]. We are suggesting that the death of damaged
hepatocytes by apoptosis may be a positive effect. There are
studies showing that caspases can induce proliferation of
neighboring surviving cells to replace dying cells in a process
referred to as “apoptosis-induced proliferation” that may be
critical for stem cell activity and tissue regeneration [35]. It
is possible that such impact on proliferation occurred at later
times, that is, after 72 hours, and therefore was not detected in
our study. In addition, the death of damaged cells by apoptosis
involves less cell leakage and recruitment of inflammatory
cells [37] and the therapeutic modulation of apoptosis may
represent a valid strategy for the treatment of human liver
diseases [38]. Thus, the paracrine effect of BMMC induces
Caspase 3, which may result in proper balance between cell
death and division during liver regeneration.
5. Conclusions
In summary, BMMC regulate immune response and promote
apoptosis in the liver after 90% PH by paracrine factors.
These changes ultimately may be related to the higher
survival observed in treated animals. Therefore BMMC are
a promising alternative to treat acute liver failure.
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whole bone marrow cells improve survival in wistar rats after
90% partial hepatectomy,” Stem Cells International, vol. 2016,
Article ID 4831524, 9 pages, 2016.
[13] C. O. Kieling, A. N. Backes, R. L. Maurer et al., “The effects of
anesthetic regimen in 90% hepatectomy in rats,” Acta Cirurgica
Brasileira, vol. 27, no. 10, pp. 702–706, 2012.
[14] J. Gaub and J. Iversen, “Rat liver regeneration after 90% partial
hepatectomy,” Hepatology, vol. 4, no. 5, pp. 902–904, 1984.
[15] B. Zhang,M. Inagaki, B. Jiang et al., “Effects of bonemarrow and
hepatocyte transplantation on liver injury,” Journal of Surgical
Research, vol. 157, no. 1, pp. 71–80, 2009.
[16] O. H. Lowry, N. J. rosebrough, A. L. Farr, and R. J. Randall,
“Protein measurement with the Folin phenol reagent,” The
Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951.
[17] P. Mattar and K. Bieback, “Comparing the immunomodulatory
properties of bone marrow, adipose tissue, and birth-associated
tissuemesenchymal stromal cells,” Frontiers in Immunology, vol.
6, article no. 560, 2015.
[18] T. Itoh andA.Miyajima, “Liver regeneration by stem/progenitor
cells,” Hepatology, vol. 59, no. 4, pp. 1617–1626, 2014.
[19] T. Yi and S. U. Song, “Immunomodulatory properties of
mesenchymal stem cells and their therapeutic applications,”
Archives of Pharmacal Research, vol. 35, no. 2, pp. 213–221, 2012.
[20] U. Matte, V. L. Lagranha, T. G. De Carvalho, F. Q. Mayer, and
R. Giugliani, “Cell microencapsulation: a potential tool for the
treatment of neuronopathic lysosomal storage diseases,” Journal
of Inherited Metabolic Disease, vol. 34, no. 5, pp. 983–990, 2011.
[21] P. N. A. Martins, T. P. Theruvath, and P. Neuhaus, “Rodent
models of partial hepatectomies,”Liver International, vol. 28, no.
1, pp. 3–11, 2008.
8 Stem Cells International
[22] M.-A. Aller, M. Mendez, M.-P. Nava, L. Lopez, J.-L. A. Arias,
and J. Arias, “The value of microsurgery in liver research,” Liver
International, vol. 29, no. 8, pp. 1132–1140, 2009.
[23] S. Terai, I. Sakaida, H. Nishina, and K. Okita, “Lesson from
theGFP/CCl4model—translational research project: the devel-
opment of cell therapy using autologous bone marrow cells
in patients with liver cirrhosis,” Journal of Hepato-Biliary-
Pancreatic Surgery, vol. 12, no. 3, pp. 203–207, 2005.
[24] Z. C. Liu and M. S. Chang, “Transdifferentiation of bioencap-
sulated bone marrow cells into hepatocyte-like cells in the 90%
hepatectomized rat model,” Liver Transplantation, vol. 12, no. 4,
pp. 566–572, 2006.
[25] H. Amemiya, H. Kono, and H. Fujii, “Liver regeneration is
impaired in macrophage colony stimulating factor deficient
mice after partial hepatectomy: the role of M-CSF-induced
macrophages,” Journal of Surgical Research, vol. 165, no. 1, pp.
59–67, 2011.
[26] F. Teixeira-Clerc, M.-P. Belot, S. Manin et al., “Beneficial
paracrine effects of cannabinoid receptor 2 on liver injury and
regeneration,” Hepatology, vol. 52, no. 3, pp. 1046–1059, 2010.
[27] M. Ninomiya, K. Shirabe, T. Terashi et al., “Deceleration of
regenerative response improves the outcome of rat withmassive
hepatectomy,” American Journal of Transplantation, vol. 10, no.
7, pp. 1580–1587, 2010.
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